Download PDF
Orthopädie und Unfallchirurgie up2date 2016; 11(04): 285-301
DOI: 10.1055/s-0042-102476
Systemerkrankungen
Georg Thieme Verlag KG Stuttgart · New York

Chondrokalzinosen und sonstige Kristallarthropathien

P. P. Roessler
Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Universitätsklinkum Bonn AöR
,
D. C. Wirtz
Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Universitätsklinkum Bonn AöR
› Author Affiliations
Further Information

Publication History

Publication Date:
28 July 2016 (online)

Also available at
    Permissions and Reprints All articles of this category

Kristallarthropathien sind Stoffwechselerkrankungen der Gelenke, deren bekanntester Vertreter die Gicht ist. Daneben existieren jedoch noch eine Reihe weiterer Kristallarthropathien, deren Pathogenese und Therapie sich mitunter deutlich unterscheiden. In diesem Beitrag werden die Entitäten Chondrokalzinose, Apatitkalzinose, Ochronose, Morbus Wilson, Hämochromatose und Oxalose sowie deren Diagnostik und Therapie dargestellt.

 

  • Literatur

  • 1 Dihlmann WWM, Stäbler A. Gelenke – Wirbelverbindungen. 4. Aufl. Stuttgart: Thieme; 2010
    Search in Google Scholar
  • 2 Abhishek A, Doherty S, Maciewicz RA et al. Does chondrocalcinosis associate with a distinct radiographic phenotype of osteoarthritis in knees and hips? – a case-control study. Arthritis Care Res (Hoboken) 2016; 68: 211-216
    CrossrefPubMedSearch in Google Scholar
  • 3 Frediani B, Filippou G, Falsetti P et al. Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. Ann Rheum Dis 2005; 64: 638-640
    CrossrefPubMedSearch in Google Scholar
  • 4 Shah K, Spear J, Nathanson LA et al. Does the presence of crystal arthritis rule out septic arthritis?. J Emerg Med 2007; 32: 23-26
    CrossrefPubMedSearch in Google Scholar
  • 5 De Vere Tyndall A, Hasler P. Rheumatologie. In: Schoenenberger RA, Haefeli WE, Schifferli J, Hrsg. Internistische Notfälle. 8. Aufl. Stuttgart: Thieme; 2008
    Search in Google Scholar
  • 6 Krams M, Frahm SO, Kellner U, Mawrin C Hrsg. Kurzlehrbuch Pathologie. 2. Aufl. Stuttgart: Thieme; 2013
    Thieme ConnectSearch in Google Scholar
  • 7 Ishida T, Dorfman HD, Bullough PG. Tophaceous pseudogout (tumoral calcium pyrophosphate dihydrate crystal deposition disease). Hum Pathol 1995; 26: 587-593
    CrossrefPubMedSearch in Google Scholar
  • 8 Zhang W, Doherty M, Bardin T et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70: 563-570
    CrossrefPubMedSearch in Google Scholar
  • 9 Ruchholtz S, Wirtz DC Hrsg. Orthopädie und Unfallchirurgie essentials. 2. Aufl. Stuttgart: Thieme; 2012
    Search in Google Scholar
  • 10 Efe T, Sagnak E, Roessler PP et al. Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. Knee Surg Sports Traumatol Arthrosc 2013; 22: 345-350
    PubMedSearch in Google Scholar
  • 11 Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rheum 1996; 63: 248-254
    PubMedSearch in Google Scholar
  • 12 Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthrit Cartilage 2007; 15: 981-1000
    CrossrefPubMedSearch in Google Scholar
  • 13 Chollet-Janin A, Finckh A, Dudler J et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007; 56: 688-692
    CrossrefPubMedSearch in Google Scholar
  • 14 Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther 1997; 23: 327-331
    PubMedSearch in Google Scholar
  • 15 Zhang W, Doherty M, Pascual E et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011; 70: 571-575
    CrossrefPubMedSearch in Google Scholar
  • 16 Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet 1981; 2: 1243-1246
    CrossrefPubMedSearch in Google Scholar
  • 17 Checa A, Chun W. Rates of meniscal tearing in patients with chondrocalcinosis. Clin Rheumatol 2015; 34: 573-577
    CrossrefPubMedSearch in Google Scholar
  • 18 Carcia CR, Scibek JS. Causation and management of calcific tendonitis and periarthritis. Curr Opin Rheumatol 2013; 25: 204-209
    CrossrefPubMedSearch in Google Scholar
  • 19 Serafini G, Sconfienza LM, Lacelli F et al. Rotator cuff calcific tendonitis: short-term and 10-year outcomes after two-needle us-guided percutaneous treatment—nonrandomized controlled trial. Radiology 2009; 252: 157-164
    CrossrefPubMedSearch in Google Scholar
  • 20 De Witte PB, Selten JW, Navas A et al. Calcific tendinitis of the rotator cuff: a randomized controlled trial of ultrasound-guided needling and lavage versus subacromial corticosteroids. Am J Sports Med 2013; 41: 1665-1673
    CrossrefPubMedSearch in Google Scholar
  • 21 Buchbinder R, Roos J, Johnston R. Shock wave therapy for rotator cuff disease with or without calcification. Cochrane Database Syst Rev 2011; (1) CD008962
    PubMedSearch in Google Scholar
  • 22 Leduc BE, Caya J, Tremblay S et al. Treatment of calcifying tendinitis of the shoulder by acetic acid iontophoresis: a double-blind randomized controlled trial. Arch Phys Med Rehabil 2003; 84: 1523-1527
    CrossrefPubMedSearch in Google Scholar
  • 23 Sell S, Rehart S. Operationsatlas Orthopädische Rheumatologie. Stuttgart: Thieme; 2013
    Thieme ConnectSearch in Google Scholar
  • 24 Toussirot É, Aquaron R. Short-term efficacy of hyaluronic acid joint injections in a case of ochronotic arthropathy. J Clin Rheumatol Pract Reports Rheum Musculoskelet Dis 2013; 19: 152-153
    PubMedSearch in Google Scholar
  • 25 Suwannarat P, O’Brien K, Perry MB et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005; 54: 719-728
    CrossrefPubMedSearch in Google Scholar
  • 26 Quemeneur A-S, Trocello J-M, Ea H-K et al. Miscellaneous non-inflammatory musculoskeletal conditions. Musculoskeletal conditions associated with Wilsonʼs disease. Best Pract Res Clin Rheumatol 2011; 25: 627-636
    CrossrefPubMedSearch in Google Scholar
  • 27 Brewer GJ, Askari FK. Wilsonʼs disease: clinical management and therapy. J Hepatol 2005; 42: 13-21
    PubMedSearch in Google Scholar
  • 28 Schubert R, Mammsen C. Röntgen- und Szintigrafiebefunde des Skeletts bei Hämochromatose. Fortschr Röntgenstr 2012; 184: 143-145
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Elmberg M, Hultcrantz R, Simard JF et al. Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis: a study of 3,531 patients and their 11,794 first-degree relatives. Arthritis Care Res (Hoboken) 2013; 65: 678-685
    CrossrefPubMedSearch in Google Scholar
  • 30 Arbeitskreises Blut des Bundesministeriums für Gesundheit. Feststellung der Spendereignung und Spendetauglichkeit von Hämochromatose Merkmalsträgern. Bundesgesundheitsbl 2015; 58: 1349-1350
    CrossrefPubMedSearch in Google Scholar
  • 31 Phatak P, Brissot P, Wurster M et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010; 52: 1671-1779
    CrossrefPubMedSearch in Google Scholar
  • 32 Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol 2013; 66: 367-373
    CrossrefPubMedSearch in Google Scholar